Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135845 | 1.00 | CTSK (0.46) | CTSKCTSSKDM4EHTTSMN1; SMN2 | |
| SCHEMBL15645213 | 0.86 | CTSS (0.52) | CTSKCTSSCTSLCTSBSCN9A | |
| SCHEMBL1587151 | 0.85 | KDM4E (0.39) | CTSKCTSSKDM4EHTTSMN1; SMN2 | |
| SCHEMBL3754888 | 0.81 | PARP1 (0.38) | CTSKCTSSKDM4EHTTSMN1; SMN2 | |
| SCHEMBL1587522 | 0.81 | ITGB3 (0.57) | — | |
| SCHEMBL10323594 | 0.81 | CTSS (0.55) | CTSKCTSSHTTCTSLCTSB | |
| SCHEMBL1684539 | 0.79 | PPARA (0.48) | CTSKCTSSCTSLCTSBSCN9A | |
| SCHEMBL15646102 | 0.77 | THRB (0.43) | CTSKCTSSKDM4EHTTSMN1; SMN2 | |
| SCHEMBL8870155 | 0.76 | CTSK (0.49) | CTSKCTSSCTSLCTSB | |
| SCHEMBL13622796 | 0.75 | KDM4E (0.44) | CTSKCTSSKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20110201625-A1 | Organic Comopunds | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2300010-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201625-A1 | Organic Comopunds | OR10J3, CFTR, CLIC1 | CTSK 4313/4885CTSS 3083/4885KDM4E 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.